EP1948637A1 - Process for amorphous esomeprazole - Google Patents

Process for amorphous esomeprazole

Info

Publication number
EP1948637A1
EP1948637A1 EP05823638A EP05823638A EP1948637A1 EP 1948637 A1 EP1948637 A1 EP 1948637A1 EP 05823638 A EP05823638 A EP 05823638A EP 05823638 A EP05823638 A EP 05823638A EP 1948637 A1 EP1948637 A1 EP 1948637A1
Authority
EP
European Patent Office
Prior art keywords
esomeprazole
amorphous
water
lyophilization
omeprazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05823638A
Other languages
German (de)
French (fr)
Other versions
EP1948637A4 (en
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Rapolu Raji Reddy
Dasari Muralidhara Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hetero Drugs Ltd
Original Assignee
Hetero Drugs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Drugs Ltd filed Critical Hetero Drugs Ltd
Publication of EP1948637A1 publication Critical patent/EP1948637A1/en
Publication of EP1948637A4 publication Critical patent/EP1948637A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to a commercially viable process for preparation of amorphous esomeprazole. Thus, amorphous esomeprazole is prepared by suspending esomeprazole in water and then subjecting the suspension to lyophilization at -70°C.

Description

PROCESS FOR AMORPHOUS ESOMEPRAZOLE
FIELD QF THE INVENTION
The present invention relates to a commercially viable process for preparation of amorphous esomeprazole.
BACKGROUND OF THE INVENTION
Omeprazole, chemically 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2- pyridinyl)methyl]sulfinyl]-1 H-benzimidazole and its therapeutic uses are disclosed in European Patent No. 5129. Omeprazole is a well-known gastric acid secretion inhibitor, and is useful as an anti ulcer agent. Omeprazole has a stereogenic center at sulfur and therefore exist as two optical isomers such as R-omeprazole and S-omeprazole (esomeprazole).
The salts of the enantiomers of omeprazole are described in WO 94/27988. PCT Publication No. WO 98/28294 disclosed esomeprazole in an amorphous form, a partly crystalline form A, and a substantially crystalline form B.
PCT Publication No. WO 2004/076440 A1 described crystalline forms, Form I and Form II, of esomeprazole, and its hydrates. PCT Publication No. WO 2004/020436 A1 described amorphous hydrates of esomeprazole magnesium and process for their preparation. PCT Publication No. WO 2004/002982 A2 described amorphous form of esomeprazole free base and process for its preparation.
U.S. Patent No. 6,369,085 described crystalline forms of esomeprazole magnesium, esomeprazole magnesium dihydrate, esomeprazole magnesium trihydrate and esomeprazole potassium.
The alkaline salts of (S)-enantiomer of omeprazole (esomeprazole), the pharmaceutical preparations of these salts and the method of treatment of gastric acid-related diseases using them are disclosed in US 4,738,974, US 5,877,192 and US 5,714,504. PCT Application No. PCT/IN05/00197 describes an amorphous form of esomeprazole. Even though the process described in the patent application yields amorphous esomeprazole in Laboratory scale, we have found that there is a problem in the scale up of process. The main problem in the scale up of this process is that the development of color in the product during drying even under reduced pressure of wet product obtained.
The object of the present invention is to provide commercially viable process for pure amorphous esomeprazole. DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention, there is provided a process for amorphous form of esomeprazole.
In accordance with the present invention, a process is provided for the preparation of amorphous esomeprazole, which comprises: a) suspending esomeprazole in water; and b) subjecting the suspension obtained in step-(a) to lyophilization to remove water.
Lyophilization is preferably carried out at about -200C to -800C and more preferably at about -400C to -700C. The esomeprazole used in the process may be in any polymorphic form, hydrated form etc., can be prepared by known techniques.
The invention will now be further described by the following examples, which are illustrative rather than limiting.
Example 1
Esomeprazole (50 gm) was suspended in water (100 ml) at 250C and then stirred at the same temperature for 3 hours. Subsequently, the water was removed by lyophilization at about -700C. After isolation from the lyophilization vessel there were obtained 49.7 gm of amorphous esomeprazole (HPLC Purity:
99.89%, water content: 2.0%).
Example 2
■ Tetrahydrofuran (250 ml) and water (500 ml) were added to esomeprazole potassium salt (50 gm) at 25 - 3O0C, cooled to 200C and then the pH is adjusted to 7.5 - 8.0 with acetic acid. The reaction mass was cooled to 50C, stirred for 2 hours at 0 - 50C, filtered the mass, washed with 50 ml of chilled mixture of water and tetrahydrofuran (2 : 1 ) and again washed with water (100 ml). To the wet cake obtained was added water (100 ml) at 250C and then stirred for 30 minutes. Subsequently, the water was removed by lyophilization at about -600C. After isolation from the lyophilization vessel there were obtained 26.2 gm of amorphous esomeprazole (HPLC Purity: 99.87%, water content: 2.5%).

Claims

We claim:
1. A process for preparation of amorphous esomeprazole, which comprises: a) suspending esomeprazole in water; and b) subjecting the suspension obtained in step-(a) to lyophilization.
2. The process as claimed in claim 1 , wherein the lyophilization is carried out at
-200C to -800C.
3. The process as claimed in claim 2, wherein the lyophilization is carried out at -400C to -700C.
EP05823638A 2005-11-14 2005-11-14 Process for amorphous esomeprazole Withdrawn EP1948637A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2005/000367 WO2007054951A1 (en) 2005-11-14 2005-11-14 Process for amorphous esomeprazole

Publications (2)

Publication Number Publication Date
EP1948637A1 true EP1948637A1 (en) 2008-07-30
EP1948637A4 EP1948637A4 (en) 2010-09-08

Family

ID=38023006

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05823638A Withdrawn EP1948637A4 (en) 2005-11-14 2005-11-14 Process for amorphous esomeprazole

Country Status (3)

Country Link
US (1) US20090082572A1 (en)
EP (1) EP1948637A4 (en)
WO (1) WO2007054951A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2195309A4 (en) * 2007-10-08 2013-04-24 Hetero Drugs Ltd Polymorphs of esomeprazole salts
CN104133012B (en) * 2014-07-02 2020-01-07 北京万全德众医药生物技术有限公司 Method for measuring asenapine maleate racemate by high performance liquid chromatography

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002982A2 (en) * 2002-06-27 2004-01-08 Dr. Reddy's Laboratories Limited A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
WO2005105054A1 (en) * 2004-04-15 2005-11-10 Dr. Reddy's Laboratories Ltd. Dosage form having polymorphic stability

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE510666C2 (en) * 1996-12-20 1999-06-14 Astra Ab New Crystal Modifications
JP4681808B2 (en) * 2001-08-03 2011-05-11 チバ ホールディング インコーポレーテッド Crystal form
EA200500673A1 (en) * 2002-10-22 2005-12-29 Рэнбакси Лабораториз Лимитед AMORPHIC FORM OF SALT EZOMEPRAZOL, METHOD FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION ON ITS BASIS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002982A2 (en) * 2002-06-27 2004-01-08 Dr. Reddy's Laboratories Limited A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
WO2005105054A1 (en) * 2004-04-15 2005-11-10 Dr. Reddy's Laboratories Ltd. Dosage form having polymorphic stability

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2007054951A1 *

Also Published As

Publication number Publication date
EP1948637A4 (en) 2010-09-08
WO2007054951A1 (en) 2007-05-18
US20090082572A1 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
MX2007010705A (en) Process for the preparation of optically active derivatives of 2-(2-pyridylmethylsulfinyl)-benzimidazole via inclusion complex with 1,1'-binaphthalene-2, 2'diol.
JP4612542B2 (en) Process for the production of optically pure active compounds
KR101169471B1 (en) Process for preparing s-pantoprazole
US8420822B2 (en) Optical resolution of substituted 2-(2-pyridinylmethylsulphinyl)-1H-benzimidazoles
WO2011004387A2 (en) Process for the preparation of dexlansoprazole polymorphic forms
KR20120114356A (en) Preparation process of the sodium salt of esomeprazole
WO2007054951A1 (en) Process for amorphous esomeprazole
JP2014169302A (en) Solid form of the magnesium salt of (s)-omeprazole and method for manufacturing the same
US8354541B2 (en) Optical purification of esomeprazole
US7563812B2 (en) Amorphous esomeprazole hydrate
EP2499125B1 (en) Process for the resolution of omeprazole
CA2491118A1 (en) A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
WO2012104863A2 (en) Process for controlling the content of single enantiomer of omeprazole

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20100810

17Q First examination report despatched

Effective date: 20110614

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111228

DAX Request for extension of the european patent (deleted)